It is important to add pain management to leprosy treatment protocols. This can reduce the challenges that patients face. Read on.

All three cannabinoids reduced the electrical activity linked to Nav1.8, but CBG had the strongest effect. This suggests that CBG could be the most promising candidate for developing new pain ...

Uber says it's being taken for a ride by a network of law firms, doctors, and pain-management clinics in New York, accusing them of orchestrating fraudulen ...

The Food and Drug Administration has approved a first-of-its-kind non-opioid pain medication, providing a new option for ...

Suzetrigine, to be sold under the brand name Journavx, is the first new type of pain medicine approved by the FDA in more ...

It’s become a familiar tragedy: someone is prescribed pain medication to recover from an injury, then becomes addicted to the ...

The FDA has approved Journavx, a pain medication, offering a safer alternative to opioids. Learn about its benefits and side ...

The FDA has approved Journavx 50 mg oral tablets for the treatment of moderate to severe acute pain in adults, according to a ...

A new class of non-opioid drugs treats pain by blocking signals before they reach the brain, reducing the risk of addiction.

The FDA on Thursday approved a new class of pain medication that provides an alternative to opioids. It will be sold under the brand name Journavx.

Suzetrigine (Journavx) is the first new drug approved to treat acute pain in over 20 years and the first to be classified as ...

The U.S. Food and Drug Administration (FDA) approved Thursday a new type of prescription pain medication for moderate to severe acute pain for adults.